AzTrials
AzTrials

Asthma in ChildrenNCT07642388

Scaling up the Integrated Care Pathway for Acute Asthma to All Osakidetza Pediatric Services Through a Cluster-randomized SMART Design

A study testing Internal + External Facilitation for Implementation, Internal + External Facilitation for Sustainability and Internal Facilitation in people with Asthma in Children, run by Basque Health Service at 1 site in Spain.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

The main goal of this study is to evaluate the effectiveness of adaptive sequential implementation strategies based on facilitation in promoting the sustainable and widespread adoption and scaling up of the Integrated Care Pathway for Acute Asthma - ASMAbat across all Primary Care and Hospital Pediatric Services of… Read more about this study

Who is it for?
Ages 2 to 14 years
Conditions the study is for
Asthma in Children
What is being tested?
Internal + External Facilitation for Implementation, Internal + External Facilitation for Sustainability and Internal Facilitation
Could I receive a placebo?
No, everyone receives an active treatment
How many people
4,680 participants
Where
1 siteSpain
Study dates
1 Jul 2026to 28 Feb 2029
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 2 to 14 years
  • All sexes
  • No healthy volunteers
  • Child

Eligibility for healthcare settings:

  • All Pediatric Services (Primary Care n=108 and Hospital Care n=9) from 11 of the 13 Osakidetza Integrated Healthcare Organizations that are not currently implementing the ASMAbat Pathway.

Eligibility for professionals:

  • Primary Care pediatricians and nurses
  • Pediatricians and nurses in the Pediatric Emergency Department
  • Pediatricians and nurses on the inpatient ward
  • Pediatric Intensive Care pediatricians and nurses
  • Pediatric Pneumology pediatricians and nurses

Eligibility for patients:

Patients between 2 and 14 years that have being attended between the 1st of July 2026 and the 28th of February 2029, and with an acute episode of asthma, defined as:

  • an episode of wheezing and a previous diagnosis of asthma or with a previous episode of wheezing
  • a first episode in a child older than 2 years with a personal/family history of atopy and/or with an objective response to bronchodilators as assessed by a severity Score

Trial locations and contacts

1 site in 1 country.

Spain1 site
  • Primary Care Research Unit of Bizkaia

    Barakaldo, Bizkaia, 48903

Other trials in Spain

About this study

Official title: Scaling up the Integrated Care Pathway for Acute Asthma to All Osakidetza Pediatric Services Through a Cluster-randomized Sequential, Multiple Assignment, Randomized Trial (SMART) Design

The main goal of this study is to evaluate the effectiveness of adaptive sequential implementation strategies based on facilitation in promoting the sustainable and widespread adoption and scaling up of the Integrated Care Pathway for Acute Asthma - ASMAbat across all Primary Care and Hospital Pediatric Services of Osakidetza - Basque Health Service.

Read the detailed description

Although evidence-based, multidisciplinary approaches have demonstrated efficacy in the management of pediatric asthma, substantial variability persists in the quality and outcomes of care for children experiencing acute asthma exacerbations. The Integrated Care Pathway for Acute Asthma - ASMAbat is a structured, evidence-informed framework designed to standardize care for patients presenting mild to moderate asthma attacks. It delineates the essential steps in clinical assessment, pharmacological management, and interprofessional coordination of care. Additionally, it incorporates quality indicators relative to diagnostic accuracy, assessment of disease severity, appropriateness of medication prescription, and the experiences of families and healthcare professionals. These indicators were refined through iterative consultations with key stakeholders (clinicians, families, and implementation partners) to ensure both clinical relevance and contextual feasibility.

The current study will be conducted across all Integrated Healthcare Organizations (IHOs) within the Osakidetza-Basque Health Service. This initiative builds on previous development and validation of the ASMAbat pathway in two IHOs, where implementation was evaluated using principles of implementation science. The expanded phase aims to systematically scale and adapt the pathway across diverse organizational settings within the Basque health system to enhance the quality, consistency, and sustainability of asthma care.

Three facilitation strategies have been developed to support implementation: (1) Internal Facilitation alone (Standard Scaling); (2) combined Internal and External Implementation Facilitation (IF); and (3) combined Internal and External Sustainability Facilitation (SF). Internal Facilitation is led by Clinical Leaders, professionals embedded within the health system who promote adoption and integration of evidence-based practices among their peers. External Facilitation is provided by experts with established experience in implementation science and quality improvement. External Implementation Facilitation focuses on supporting Clinical Leaders in diagnosing and addressing barriers to practice change using the Behavior Change Wheel framework, a theoretically grounded model for analyzing determinants of individual and collective behavioral change. In contrast, External Sustainability Facilitation emphasizes the identification and reinforcement of organizational, team-level, and individual factors necessary to achieve the long-term, system-wide institutionalization of the ASMAbat pathway into routine pediatric asthma management.

The overarching objective of this study is to evaluate the effect of scaling the implementation of the ASMAbat pathway across the Basque Health Service, with the overall goal of improving clinical management of acute asthma in children in accordance to recommended care and reducing variability across professionals and care settings. The primary scientific aim is to determine, among Pediatric Services demonstrating suboptimal response to the Standard Scaling (SS) strategy, the incremental effect of adding an Implementation Facilitation component on the appropriateness of the management of acute asthma episodes, which includes: a) the recording of the severity score, b) the assessment and recording of persistent asthma symptoms using the Pediatric Asthma Control Tool (M-PACT), c) the initiation or adjustment of maintenance treatment in cases of persistent asthma symptoms, and d) the administration of bronchodilator treatment via MDI with a spacer device. Secondary aims include evaluating, among services achieving adequate initial adoption through SS, the effect of introducing a Sustainability Facilitation strategy compared with maintaining SS alone during the subsequent phase, on the indicators of adequacy in the management of acute asthma episodes.

A Cluster-randomized Sequential Multiple Assignment Randomized Trial (SMART) design will be employed to test adaptive implementation strategies. All pediatric professionals belonging to 11 IHOs from Osakidetza-Basque Health Service and all acute asthma episodes in children aged 2-14 years during the study period will be included. During the first 8 months, all centers will receive the universal components of the ASMAbat Pathway and will be exposed to a standard scaling strategy (SS) composed of training for Clinical Leaders and pediatric professionals, electronic health record decision-support tools, audit and feedback, multichannel dissemination, and email reminders.

At month 8, based on the achieved implementation response (success criterion = Pulmonary Score recording rate exceeding 40% of all acute asthma episodes managed during the observation), external facilitation may be sequentially and randomly added as an adaptive strategy: for sites with poor adoption, facilitation will target barrier identification, problem-solving, and behavioural determinants; for sites with successful adoption, it will focus on sustainability by integrating the pathway into routine care. A second random reassignment will be conducted at month 16 based on response status, followed by an 8-month maintenance period, with a total follow-up of 32 months across all centers. Changes between periods by strategy in the rates of mild-to-moderate acute asthma episodes in which recommended treatment administration is recorded will be analysed using generalised linear mixed models. Implementation outcomes of reach and adoption of recommended care at patient and professional levels, fidelity of the clinical and implementation strategies, professionals' perceived feasibility, and user-reported care satisfaction will also be assessed.

This present study's design aims to maximize efficiency by first deploying the least complex, resource-intensive strategy and sequentially intensifying or modifying facilitation for sites demonstrating limited response, while maintaining existing strategies for successful sites. Such an adaptive approach minimizes costs by tailoring the level of implementation support to each site's readiness and observed progress. Furthermore, this design enhances the potential for scalability and generalizability across multiple contexts, including different clinical settings, patient subpopulations, and organizational environments. Ultimately, the project seeks to advance system-wide adoption and sustainability of evidence-based clinical practice for pediatric asthma management within Osakidetza, contributing to the broader field of implementation science and healthcare quality improvement.

Being tested
Internal + External Facilitation for Implementation, Internal + External Facilitation for Sustainability, Internal Facilitation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Internal + External Facilitation for ImplementationBehavioural

    Non-responding sites randomized to receive both internal and external facilitation focused on addressing determinants (barriers) of low adoption

  • Internal + External Facilitation for SustainabilityBehavioural

    Responding sites randomized to receive both internal and external facilitation focused on consolidate factors required for sustained adoption

  • Internal FacilitationBehavioural

    Both responding and non-responding randomized to receive the standard scaling

Study groups in NCT07642388
Study groupRoleWhat they receive
Implementation facilitation (IF) strategyExperimentalStandard scaling up of the clinical pathway augmented with Implementation Facilitation
Receives: Behavioral: Internal + External Facilitation for Implementation
Sustainability facilitation (SF) strategyExperimentalStandard scaling up of the clinical pathway augmented with Sustainability Facilitation
Receives: Behavioral: Internal + External Facilitation for Sustainability
Standard scaling (SS) strategyActive comparatorStandard scaling up of the clinical pathway
Receives: Behavioral: Internal Facilitation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in the registration rate of bronchodilator treatment

    Between-period change by strategy (e.g., the change from month 8 to month 16 under one strategy compared with the corresponding change under another strategy) in the rates of mild-to-moderate acute asthma episodes with documented administration of bronchodilator therapy delivered via MDI with spacer device.

    Measured: Change from period 1 (baseline to 8 months) to period 2 (8 to 16 months); from period 1 or 2 to period 3 (16 to 24 months); and from period 3 to period 4 (24 to 32 months)

Secondary outcomes (3)
  1. Change in the registration rate of Pulmonary Score

    Between-period change by strategy in the rates of registration of Pulmonary Score in children diagnosed with mild-moderate asthma attacks. The Pulmonary Score has a scale range of 0-9 with lower values representing better outcomes.

    Measured: Change from period 1 (baseline to 8 months) to period 2 (8 to 16 months); from period 1 or 2 to period 3 (16 to 24 months); and from period 3 to period 4 (24 to 32 months)

  2. Change in the registration rate of persistent asthma symptoms

    Between-period change by strategy in the rate of registration of persistent asthma symptoms in children diagnosed with mild-moderate asthma attacks using the M-PACT form (Mini-Pediatric Asthma Control Tool).

    Measured: Change from period 1 (baseline to 8 months) to period 2 (8 to 16 months); from period 1 or 2 to period 3 (16 to 24 months); and from period 3 to period 4 (24 to 32 months)

  3. Change in the registration rate of the initiation of background treatment in children with persistent asthma symptoms

    Between-period change by strategy in the rate of registration of initiation of background treatment in children with persistent asthma symptoms.

    Measured: Change from period 1 (baseline to 8 months) to period 2 (8 to 16 months); from period 1 or 2 to period 3 (16 to 24 months); and from period 3 to period 4 (24 to 32 months)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Jun 2026
  2. Study start1 Jul 2026
  3. Primary completion28 Feb 2029 (estimated)
  4. Study completion28 Feb 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Randomised
Intervention model
Sequential
Model description
Cluster-randomized Sequential, Multiple Assignment, Randomized Trial (SMART)
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
4,680 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07642388
Sponsor's protocol ID
PI2026062
Status last verified
Jun 2026
First submitted
8 Jun 2026
Last updated
1 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Individual participant data will be shared that underlie results reported in the publication, after deidentification.

Questions about this trial

What is this clinical trial studying?

A study testing Internal + External Facilitation for Implementation, Internal + External Facilitation for Sustainability and Internal Facilitation in people with Asthma in Children, run by Basque Health Service at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 1 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in the registration rate of bronchodilator treatment (time frame: Change from period 1 (baseline to 8 months) to period 2 (8 to 16 months); from period 1 or 2 to period 3 (16 to 24 months); and from period 3 to period 4 (24 to 32 months)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in